Evidence map›Paper›PMID 41258594›Full record

ArticleIndian pediatrics2026

Use of Infliximab in Infantile Kawasaki Disease: Experiences over 8 Years.

C Ravali Pratima Goud, Rhea Singh, Anindita Nandi, Jigna N Bathia, Priyankar Pal

Abstract read
PubMed Publisher
In one paragraph

Article in Indian pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

C Ravali Pratima GoudPediatric Rheumatology Unit, Institute of Child Health, Dr Biresh Guha Street, Park Circus, Kolkata, India.ORCID 0009-0006-6272-9069
Rhea SinghPediatric Rheumatology Unit, Institute of Child Health, Dr Biresh Guha Street, Park Circus, Kolkata, India.
Anindita NandiPediatric Rheumatology Unit, Institute of Child Health, Dr Biresh Guha Street, Park Circus, Kolkata, India.
Jigna N BathiaPediatric Rheumatology Unit, Institute of Child Health, Dr Biresh Guha Street, Park Circus, Kolkata, India.
Priyankar PalPediatric Rheumatology Unit, Institute of Child Health, Dr Biresh Guha Street, Park Circus, Kolkata, India. mailme.priyankar@gmail.com.ORCID 0000-0003-3273-6218

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Data on the use of infliximab (IFX) in infants with Kawasaki disease (KD) are scant. We retrospectively analyzed data of 35 infants with KD who received IFX. Effectiveness of IFX was assessed in the presence of intravenous immunoglobulin (IVIG) resistance and coronary artery aneurysm (CAA) regression. Fifteen of thirty-five received IFX in the presence of IVIG resistance; nineteen of thirty-five for CAA; and one for persistently high c-reactive protein. Thirteen out of fifteen with IVIG resistance became afebrile by 24 h. Twelve medium CAA regressed over 3 months, four of ten giant CAA normalized, and three regressed to small CAA, median time being 7.5 (3.5, 18) months. IFX was well-tolerated, safe, and effective in infants with KD.

Indexed as

InfliximabMucocutaneous Lymph Node SyndromeCoronary AneurysmFemaleHumansImmunoglobulins, IntravenousInfantMaleRetrospective StudiesTreatment OutcomeImmunoglobulins, IntravenousInfliximabAnti-tumor necrosis factor-alphaCoronary artery aneurysmIVIG resistanceRefractory Kawasaki diseaseTNF-α

Identifiers

PMID41258594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.